Ore Holdings Inc. (fka ORXE)

[acgood]

they should and probably are trying to

[Stock]

sell the company today then

[acgood]

but the cash will be gone sometime in Q3. Or sooner if they start another trial.

[Stock]

$10.8M cash / 5.4M shares = $2.00 per share cash

[Stock]

Time & Sales
Price Size Exch Time
0.51 286 NGS 16:00:03
0.75 564 NGS 15:58:55
0.74 100 NGS 15:58:55
0.74 100 NGS 15:58:55
0.70 1500 NGS 15:58:55
0.70 756 NGS 15:58:55
0.69 100 NGS 15:58:55
0.69 100 NGS 15:58:55
0.67 1450 NGS 15:58:54
0.66 100 NGS 15:58:54
0.66 100 NGS 15:58:54
0.66 800 NGS 15:58:54
0.65 100 NGS 15:58:54
0.65 100 NGS 15:58:53
0.64 100 NGS 15:58:53
0.64 100 NYE 15:58:53
0.62 2400 NDD 15:58:53
0.62 1000 NDD 15:58:53
0.62 530 NDD 15:58:53
0.56 100 NDD 14:53:42
0.56 3400 NDD 13:47:48
0.58 5000 NYE 11:36:49
0.58 9000 NYE 11:35:39
0.58 100 NDD 11:35:38
0.55 100 NDD 10:59:12
0.58 1400 NGS 10:16:04
0.58 100 NDD 10:16:03
0.58 1400 NDD 10:10:52
0.58 84600 NGS 10:10:52
0.5799 100 NGS 10:08:23

[Stock]

had news today

[Stock]

Ore Pharma Announces Sale Of DioGenix Unit To Nerveda
Last update: 9/23/2008 7:26:03 AM

DOW JONES NEWSWIRES

Ore Pharmaceuticals Inc. (ORXE) disclosed Tuesday that its DioGenix unit was sold to Nerveda Inc., a privately held specialty pharmaceutical and diagnostic company.

The company said in a document filed with the Securities and Exchange Commission that its former unit was sold for an undisclosed amount of cash, as well as a small royalty on sales of a multiple sclerosis diagnostic. [the reporter did not read the filing, it's in there]

Under the terms of the pact, Nerveda will fund DioGenix with at least $5 million to accelerate and expand proprietary programs, led by blood-based tests for the diagnosis and clinical management of multiple sclerosis.

According to the filing, the DioGenix senior management team will continue in their current roles supported by financial and strategic management resources provided by Nerveda.

Shares of the biotechnology company closed Monday at 83 cents.

-By Chad Clinton, Dow Jones Newswires; 202-862-1349; [e-mail]

[Stock]

Nerveda, Inc

3888 Quarter Mile Dr, San Diego, CA 92130-1291, United States (Map)

Phone: [phone]

SIC:Pharmaceutical Preparations

Line of Business:Mfg Pharmaceutical Preparations

Ads by Google

DPT Laboratories The industry source for semi-solids and liquids.

Analytical Chemistry Mass Spectra, NMR and HPLC Fast PDF service from $59 ea.

The ads are not affiliated with Nerveda, Inc

Detailed Nerveda, Inc Company Profile
This company profile is for the private company Nerveda, Inc, located in San Diego, CA. Nerveda, Inc's line of business is mfg pharmaceutical preparations.


Company Profile: Nerveda, Inc

Year Started:2007

State of Incorporation:N/A

URL:N/A

Location Type:Single Location

Stock Symbol:N/A

Stock Exchange:N/A

Also Does Business As:N/A

NAICS:N/A

SIC #Code:2834

Est. Annual Sales:$100,000

Est. Employees:1

Est. Employees at Location:1

Contact Name:Cam Gallagher

Contact Title:President

Data above provided by D&B.

Additional Information on Nerveda, Inc

[Stock]

Entry into a Material Definitive Agreement.

On September 19, 2008, Ore Pharmaceuticals Inc. (the “ Company ”) sold to Nerveda Inc. the Company’s wholly owned subsidiary, DioGenix, focused on molecular diagnostics, pursuant to a stock purchase agreement (the “ Stock Purchase Agreement ”). The purchase price for the stock was $1.25 million (the “ Purchase Price ”), consisting of $500,000 paid at closing and $750,000 payable pursuant to a promissory note from DioGenix with two principal payments of $375,000 each due on December 31, 2009 and June 30, 2010, respectively. Payments due under the note are subject to acceleration if DioGenix secures institutional investments or reaches a certain development milestone. The Note is secured by a lien on DioGenix assets. If DioGenix commercializes a diagnostic product or service for multiple sclerosis, DioGenix would pay Ore Pharmaceuticals a royalty equal to 3.5 percent of net sales of such tests and services, capped at an aggregate of $1.5 million. The Company and Nerveda have each agreed to indemnify each other for breach to any representation, warranty, covenant or obligation made pursuant to the Stock Purchase Agreement.

The above description of the Stock Purchase Agreement is qualified in its entirety by reference to the complete terms of the Stock Purchase Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

---

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On September 19, 2008, Larry Tiffany, a Senior Vice President of the Company, and President of the Company’s wholly owned subsidiary, DioGenix, resigned as an officer and employee of the Company and DioGenix, effective as of September 14, 2008, in connection with the sale of DioGenix to Nerveda, as described in Item 1.01 above. In connection with his resignation, Mr. Tiffany waived the right to any further payments otherwise due under his existing employment agreement.

Item 8.01. Other Events.

On September 23, 2008, DioGenix issued a press release announcing the Stock Purchase Agreement. That press release is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit Number
Description

10.104
Stock Purchase Agreement dated as of September 19, 2008 by and among Ore Pharmaceuticals Inc. and Nerveda, Inc.

99.1
Press Release issued by DioGenix Inc. dated September 23, 2008 with respect to the sale of DioGenix to Nerveda, Inc.

--------------------------------------------------------------------------------

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


ORE PHARMACEUTICALS INC.


Date: September 23, 2008
By: /s/ Philip L. Rohrer Jr.

Philip L. Rohrer Jr.
Chief Financial Officer
--------------------------------------------------------------------------------

EXHIBIT INDEX

Exhibit Number
Description

10.104 Stock Purchase Agreement dated as of September 19, 2008 by and among Ore Pharmaceuticals Inc. and Nerveda.


99.1 Press Release issued by DioGenix Inc. dated September 23, 2008 with respect to the sale of DioGenix to Nerveda

http://ih.advfn.com/p.php?pid=nmona&cb=1222175289&article=28266311&symbol=N%5EORXE

[Stock]

Volume highest it's been in months of weeks.

[Stock]

Now below a dollar.

[Stock]

unusual volume at the open today




http://evolveordie.us/

[Stock]

the stock has a bid in after hours. that's different.

[Stock]

ORXE Share Statistics:

Outstanding -- 5,503,092
Float -- 5,271,710

http://ih.advfn.com/p.php?pid=squote&symbol=ORXE


http://worldwidewas.com/

[acgood]

market cap 6.5 mil for theoretically two phase 2 and one phase 1 compounds...

an attractive proposition at some point here or will this management destroy another business model?

[Stock]

ORXE 5 minute 3 day chart

[Stock]

ORXE weekly charts

[Stock]

ORXE daily charts

[Stock]

Market cap now $6.5M for ORXE

[Stock]

ORXE - Ore Pharmaceuticals Files Investigational New Drug Application with FDA

Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for GL1001, the first clinical-stage inhibitor of the ACE2 enzyme. This orally administered small molecule is being developed primarily for inflammatory bowel disease (IBD). Treatment with GL1001 has decreased several disease activity measures in in vivo models of IBD as well as other gastrointestinal diseases with related injury due to inflammation. GL1001 was previously administered in a Phase I single ascending dose clinical study completed in the United Kingdom, where it was well tolerated and exhibited pharmacokinetics consistent with once daily dosing.

Pending clearance of the IND, the Company plans to initiate a multiple ascending dose clinical trial in September 2008 to assess tolerability, pharmacokinetics and pharmacodynamics of GL1001. Additionally, Ore Pharmaceuticals is undergoing preparations to test this first-in-class compound in later-stage clinical trials. The Company is pursuing the clinical development of GL1001 in parallel with its efforts to establish an out-licensing or partnering arrangement to advance the compound into later-stage clinical trials.

Ore Pharmaceuticals used its proprietary Indication Seeking Program to reposition GL1001 from the indication of obesity pursued by the original sponsor to IBD (which includes ulcerative colitis and Crohn’s disease). Company data indicate additional potential applications in related conditions such as gastritis, prevention or healing of gastric ulcer secondary to NSAIDs, and pancreatitis. Ore Pharmaceuticals has an extensive intellectual property estate of issued patents for GL1001 covering both the drug target and compound chemistry through at least 2020.

Ore Pharmaceuticals Chief Executive Officer, Charles L. Dimmler, III, commented, “The filing of the first IND in the Company’s history is a significant milestone for Ore Pharmaceuticals. We expect this first-in-class compound to be an attractive in-licensing candidate for pharmaceutical companies.” Ore Pharmaceuticals Senior Vice President, Clinical Development, Stephen Donahue, M.D., said, “We are pleased to resume clinical development of GL1001, a novel compound of high quality that offers significant opportunity as a potential oral treatment of IBD that may be added to any of the existing therapies.” “We feel that the new indication is well-supported by the data that Ore generated,” said Thomas Barnes, Ph.D., SVP of Discovery. “GL1001 was the first molecule we attempted to reposition and the success of our integrative pharmacology technology in identifying IBD and other GI inflammatory diseases is a testament to the robustness of the platform. By observing an anti-inflammatory mechanism, spatially confined to the GI tract and its accessory organs, we were able to create and refine our hypothesis for the treatment of IBD.” About Inflammatory Bowel Disease IBD is a chronic and often debilitating disorder characterized by inflammation and scarring in the digestive tract. There are two main types of inflammatory bowel disease: ulcerative colitis and Crohn's disease, and the conditions affect approximately one million patients in the United States. Although the underlying etiology of this relapsing and remitting disease is unknown, it involves genetic, environmental and immunologic factors. Current treatments have significant limitations in effectiveness or cause adverse events of varying severity.

Ore Pharmaceuticals Overview Ore Pharmaceuticals is a commercial drug development company. We have applied our proprietary know how in integrative pharmacology to identify potential new uses for drug candidates. We are now focused on developing certain compounds for which we have found such new uses. Our goal is to meet the demands of the pharmaceutical industry by supplying development stage drug compounds to enrich drug development pipelines. We currently have a lead compound, GL1001, in our own development pipeline for which we have identified potential new therapeutic uses to treat gastrointestinal inflammation, including inflammatory bowel disease (IBD, including ulcerative colitis and Crohn’s disease) and other conditions. GL1001 has shown indications of efficacy at relevant doses in in vivo testing for IBD. We intend to initiate clinical testing of GL1001 in 2008 while actively seeking to out-license or partner the further clinical development and commercialization of the compound. We have rights to develop additional compounds that have been tested in clinical stage testing by our partners but that are in later stages of preclinical testing for the uses we have discovered. Visit us at orepharma.com or call 1-877-ORE-PHRM.

Safe Harbor Statement This press release contains "forward-looking statements," as such term is used in the Securities Exchange Act of 1934, as amended. Such forward-looking statements include the Company's ability to identify strategies for making its businesses successful and the impact of such strategies on our business and financial performance and on shareholder value. Forward-looking statements typically include the words "expect," "anticipate," "believe," "estimate," "intend," "may," "will," and similar expressions as they relate to Ore Pharmaceuticals or its management. Forward-looking statements are based on our current expectations and assumptions, which are subject to risks and uncertainties. They are not guarantees of our future performance or results. Our actual performance and results could differ materially from what we project in forward-looking statements for a variety of reasons and circumstances, including particularly risks and uncertainties that may affect the Company's operations, financial condition and financial results and that are discussed in detail in the Company's Annual Report on Form 10-K and our other subsequent filings with the Securities and Exchange Commission. They include, but are not limited to: whether we can obtain from our partners development rights to repositioned compounds; whether we can successfully develop to a sufficient stage and outlicense repositioned compounds on acceptable terms and whether such outlicensed compounds are then successfully developed and commercialized and generate sales and resulting milestone payments from development and royalties from sales for the Company,; whether we will be able to begin to generate sufficient new revenue from licensing or other transactions soon enough to support our operations; whether there will be valid claims for indemnification from the buyers of our Genomics Assets; whether there will be claims from the landlords of the leased properties we have assigned to buyers of our Genomics Assets or our Preclinical Division that we would be required to pay as guarantors of such leases; whether we will be able to collect amounts due under the terms of the promissory note from the buyer of our Genomics Assets; whether we will be able to manage our existing cash adequately and whether we will have access to financing on sufficiently favorable terms to maintain our businesses and effect our strategies, including development of repositioned compounds; whether we will be able to recruit and retain qualified personnel for our commercial drug development business; whether we will be able to find a sufficiently attractive strategic option to develop our molecular diagnostics capability that does not require significant use of our financial assets; potential negative effects on our operations and financial results from workforce reductions and the transformation of our business; and the possibility of further write-down of the value of certain intangible assets of the Company. Ore Pharmaceuticals Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

http://ih.advfn.com/p.php?pid=nmona&cb=1214948910&article=27129882&symbol=N%5EORXE

[Stock]

IB has 85k to borrow. so maybe not?

[Stock]

someone forced to cover a short this morning? 1.50 x 20,000?

that's $30,000 worth of stock. lol

or maybe an insider. watch for a Form 3/4 in a couple of days.

t trade, so it's a late print, at least according to the tape. 7 days late? must be a forced short cover. that's the last time the stock was 1.50. 7 days ago. the float is very small on this stock.

Time & Sales
Price Size Exch Time
t 1.50 20000 NDD 09:29:58

[Stock]

DioGenix Discovers Gene Sets Which Correlate to Multiple Sclerosis

Last update: 6/9/2008 1:23:01 PM

Will Conduct Follow-On Studies to Develop MS Diagnostics

GAITHERSBURG, Md., Jun 09, 2008 (BUSINESS WIRE) -- Ore Pharmaceuticals Inc. (ORXED) announced today that DioGenix, its molecular diagnostics subsidiary, has identified novel sets of genes that it believes will form the basis of a new assay to diagnose multiple sclerosis (MS), a disease of the central nervous system (CNS). DioGenix plans to refine these gene sets and further confirm their disease association before it begins to develop an effective commercial assay for diagnosing patients presenting with early symptoms of MS. The Company is seeking strategic alternatives to fund DioGenix's product development efforts. To discover these correlative gene sets, DioGenix scientists compared gene expression profiles from a genome-wide analysis of whole blood samples from MS patients, patients with alternative diseases which mimic MS and samples collected from normal donors. The scientists found statistically significant differences in gene expression between the groups, resulting in a novel gene set now covered by the Company's recent international patent filing. This work confirmed the results of an earlier DioGenix study, based on peripheral blood mononuclear cells, announced in an October 2007 press release. "This most recent study continues to provide encouraging evidence that we are on the right path to develop a clinically relevant diagnostic for MS," said Larry Tiffany, Chief Executive of DioGenix. "A blood-based test that can diagnose MS would improve the quality of care for patients who currently must endure a lengthy, costly and invasive medical work-up, even in those cases where MS cannot be definitively diagnosed. This is the first phase of our MS program, as we build on our knowledgebase of MS disease biology and work to find markers that can monitor disease activity, identify sub-types of MS, and assess therapeutic activity." MS is a chronic inflammatory disease that selectively destroys the myelin sheaths of neurons within the CNS, leading to loss of neurological function with unpredictable course and severity. In the United States alone, the disease affects approximately 400,000 persons and up to 25,000 new cases are diagnosed each year. Susceptibility to MS is determined by genetic and environmental factors that are not well understood. Current methods of diagnosis require a battery of expensive and, in many cases, invasive tests -- including lumbar puncture to access cerebral spinal fluid -- that often do not result in an accurate diagnosis. About DioGenix DioGenix, Inc., a wholly owned subsidiary of Ore Pharmaceuticals, is a molecular diagnostics enterprise focused on the development and commercialization of novel non-invasive diagnostic, prognostic and treatment response monitoring tests. DioGenix was formed to leverage the significant capital and human resources invested by Gene Logic in the development of a unique set of assets and capabilities. For the past ten years, the DioGenix management team has been working with the world's largest pharmaceutical companies to identify and exploit biomarkers that correlate with disease activity and therapeutic response, primarily utilizing the tools that are now core assets of DioGenix. Over this period, these assets and the well-established methods for their use have been optimized to a performance level and quality required for diagnostic, as well as pharmaceutical, development. The DioGenix team's efforts have led to identification of a number of opportunities with significant market appeal that could be developed on an accelerated schedule. DioGenix's lead program is designed, for the first time, to provide neurologists with a comprehensive set of clinical tests to diagnose early-stage MS, segment MS patients into clinical sub-types and predict response to treatment, all using non-invasive blood tests. Over time, DioGenix plans to utilize its unique assets and capabilities to develop additional tests for indications of significant clinical relevance. SOURCE: Ore Pharmaceuticals Inc.
DioGenix Contact Info:Larry TiffanyChief Executive Officer, DioGenixInterim Head, Commercial OperationsOre Pharmaceuticals [e-mail] Business Wire 2008

[Stock]

ORXED real time 10 day 15 minute period chart

[Stock]

ORXED Weekly Charts

[Stock]

ORXED daily charts

[Teamlasvegas]

May 23, 2008 - 2:15 PM EDT

ORXE 0.333 -0.007

Ore Pharmaceuticals Shareholders Approve One-for-Five Reverse Stock Split, Re-Election of Two Directors
Reverse stock split to be effective at 5:00 PM Eastern Time

Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that, at its annual meeting, its stockholders approved a proposed one-for-five reverse stock split of the Company’s common stock, re-elected directors J. Stark Thompson, Ph.D. and Mark Gessler to terms expiring in 2011, and ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2008.

The reverse stock split becomes effective as of 5:00 PM Eastern Time today, and will reduce the number of outstanding shares of the Company’s common stock from approximately 27.5 million shares to approximately 5.5 million shares. Ore Pharmaceuticals’ stock will trade under the symbol “ORXED” for 20 trading days to reflect the split, in compliance with NASDAQ rules, and will thereafter resume trading under the Company’s symbol “ORXE.”

The reverse stock split is intended to enable the Company to regain compliance with the NASDAQ Global Market’s minimum closing bid price requirement. As previously announced, NASDAQ notified the Company in December 2007 that the Company’s stock had closed below the $1.00 minimum bid price requirement for 30 consecutive trading days and had until June 11, 2008 to regain compliance with this requirement for continued listing on the NASDAQ Global Market. If the Company maintains a minimum closing bid price of $1.00 or more per share for a minimum of 10 consecutive trading days prior to June 11, 2008, the Company expects that it will receive a notification from NASDAQ that it has regained compliance with the listing requirement.

Ore Pharmaceuticals Overview

Ore Pharmaceuticals is a commercial drug development company. We apply our proprietary know how in integrative pharmacology to identify potential new uses for drug candidates. Our goal is to meet the demands of the pharmaceutical industry by supplying development stage drug compounds to enrich drug development pipelines. We do this in two ways: We identify uses for stalled or failed drug compounds provided by our pharmaceutical partners, and, for our own pipeline, we identify new uses for drug compounds available in the public domain. Our own pipeline may also include compounds that our pharmaceutical partners decide not to develop for new uses we identify. We currently have one compound, GL1001, in our own development pipeline for which we have identified potential new therapeutic uses to treat gastrointestinal inflammation, including inflammatory bowel disease (IBD, including ulcerative colitis and Crohn’s disease) and other conditions. GL1001 has shown indications of efficacy at relevant doses in in vivo testing for IBD. We intend to initiate clinical testing of GL1001 in 2008 while actively seeking to out-license or partner the further clinical development and commercialization of the compound. Visit us at orepharma.com or call 1-877-ORE-PHRM.


Ore Pharmaceuticals Inc.
Philip L. Rohrer, Jr. (investors)
Chief Financial Officer
301-361-4400
[e-mail]
or
Christopher Culotta (investors and media)
Senior Director, Strategic Communications
240-361-4433
[e-mail]




Source: Business Wire (May 23, 2008 - 2:15 PM EDT)

News by QuoteMedia
www.quotemedia.com

[Stock]

Ore Pharmaceuticals CEO Charles Dimmler Presents Compound Status and Patent Development at Rodman & Renshaw 5th Annual Global Healthcare Conference

Monday May 19, 3:20 am ET

Seeks Out-Licensing of IBD Drug Candidate, Announces Publishing of Patent Application Related to Breast Cancer Therapy


GAITHERSBURG, Md.--(BUSINESS WIRE)--Ore Pharmaceuticals Inc. (NASDAQ: ORXE - News) announced today that Chief Executive Officer and President Charles L. Dimmler, III, gave a presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference, that included certain research and development findings, the Company’s current compound development status, and information about its recently published patent application regarding stratification and treatment of the majority of breast cancer patients based on their estrogen receptor alpha status.

Research and Development Findings

Mr. Dimmler presented the Company’s findings resulting from its integrative pharmacology capability. Ore Pharmaceuticals uses a multi-pronged approach to discover new therapeutic indications for drugs and drug candidates. The Company has evaluated more than 100 compounds and, for 28 of those compounds, has found a potential new therapeutic use. To date, eight of those compounds have yielded positive results for the potential new therapeutic use in in vivo efficacy tests, and four additional compounds are currently being tested in such models. Ore Pharmaceuticals expects to acquire two to three of these compounds each year for its own clinical development pipeline.

Pipeline Status

Ore Pharmaceuticals’ lead drug candidate in its development pipeline is GL1001, a first-in-class, orally administered small molecule. Mr. Dimmler presented preclinical data validating the beneficial effect of GL1001 in a model of ulcerative colitis, and showing the protective effect of GL1001 on gastritis induced by nonsteroidal anti-inflammatory drugs. Ore Pharmaceuticals plans to submit an investigational new drug (IND) application to the FDA in late June and, pending approval, will proceed with a clinical trial of GL1001 in September. The Company plans to acquire and then out-license additional compounds for its development pipeline.

AT1-R Status and Background

Mr. Dimmler also discussed the Company’s patent applications related to angiotensin II type I receptor (AT1-R) status as a determinant for stratifying and treating infiltrating ductal carcinoma (IDC) of the breast. Ore Pharmaceuticals has discovered a correlation, in patients with IDC of the breast, between estrogen receptor alpha positive (ER+) status and angiotensin II type I receptor (AT1-R) mRNA expression. The Company’s scientists found that upregulation of AT1-R is present in IDC patients who are ER+ and that ER+ IDC tumor cells responded to pharmacologic intervention with AT1-R antagonists. Ore Pharmaceuticals has supported its findings using in vitro and in vivo models. The findings could help stratify breast cancer patients, thereby facilitating more effective treatment with AT1-R antagonists either alone or in combination with other therapies. The Company’s patent filing claims include:

A method of selecting female breast cancer patients for appropriate treatment

A method for treating a segment of breast cancer patients

A method for determining whether breast cancer tumors are responsive to selective estrogen receptor modulator treatment

Mr. Dimmler also presented preclinical data showing that the activity of an AT1-R antagonist (candesartan, a hypertension drug) is similar to that of tamoxifen, a selective estrogen receptor modulator used in treating breast cancer for decades. The Company has additional studies under way in other breast cancer models, and is seeking to out-license the intellectual property to a pharmaceutical company with a currently marketed angiotensin II type I receptor antagonist.

Breast cancer is the leading cause of cancer-related mortality among women worldwide. In 2006, more than 450,000 cases of the disease were diagnosed in the seven major pharmaceutical markets, 75% of which were diagnosed as infiltrating ductal carcinoma, a cancer type with a propensity to metastasize via the lymphatic system to other tissues and organ systems. Despite recent drug approvals in the adjuvant and metastatic setting, high unmet needs still persist for this tumor type as the overall survival rate remains below five years.

Charles L. Dimmler, III, Ore Pharmaceuticals CEO and President, commented, “Ore Pharmaceuticals is advancing drug candidates based on our proprietary integrative pharmacology. Our program identifies new indications for safe, undervalued drug candidates, and, we believe, could extend the value and competitive viability of marketed drugs. We are pleased with the data related to GL1001 and believe it is an excellent candidate for out-licensing or co-development in IBD and related diseases, which are areas of large unmet medical need. Additionally, our AT1-R findings represent an opportunity to extend the use and patent life of existing therapies while offering significant benefit to a large number of breast cancer patients.”

Presentation Available

Mr. Dimmler’s presentation is archived on the Ore Pharmaceuticals web site at www.orepharma.com.

Ore Pharmaceuticals Overview

Ore Pharmaceuticals is a commercial drug development company. We apply our proprietary know how in integrative pharmacology to identify potential new uses for drug candidates. Our goal is to meet the demands of the pharmaceutical industry by supplying development stage drug compounds to enrich drug development pipelines. We do this in two ways: We identify uses for stalled or failed drug compounds provided by our pharmaceutical partners, and, for our own pipeline, we identify new uses for drug compounds available in the public domain. Our own pipeline may also include compounds that our pharmaceutical partners decide not to develop for new uses we identify. We currently have one compound, GL1001, in our own development pipeline for which we have identified potential new therapeutic uses to treat gastrointestinal inflammation, including inflammatory bowel disease (IBD, including ulcerative colitis and Crohn’s disease) and other conditions. GL1001 has shown indications of efficacy at relevant doses in in vivo testing for IBD. We intend to initiate clinical testing of GL1001 in 2008 while actively seeking to out-license or partner the further clinical development and commercialization of the compound. Visit us at orepharma.com or call 1-877-ORE-PHRM.

Contact:
Ore Pharmaceuticals Inc.
Philip L. Rohrer, Jr. (investors)
Chief Financial Officer
301-361-4400
[e-mail]
or
Christopher Culotta (investors and media)
Senior Director, Strategic Communications
240-361-4433
[e-mail]

--------------------------------------------------------------------------------
Source: Ore Pharmaceuticals Inc.

http://biz.yahoo.com/bw/080519/20080519005591.html?.v=1

=============== ADVFN VERSION ===================

Ore Pharmaceuticals CEO Charles Dimmler Presents Compound Status and Patent Development at Rodman & Renshaw 5th Annual Global He
Date : 05/19/2008 @ 2:20AM
Source : Business Wire
Stock : Ore Pharmaceuticals Inc. (ORXE)
Quote : 0.36 0.0 (0.00%) @ 8:02AM
<< Back Quote Chart Financials Trades


Ore Pharmaceuticals CEO Charles Dimmler Presents Compound Status and Patent Development at Rodman & Renshaw 5th Annual Global He


Ore Pharmaceuticals Inc. (NASDAQ: ORXE) announced today that Chief Executive Officer and President Charles L. Dimmler, III, gave a presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference, that included certain research and development findings, the Company’s current compound development status, and information about its recently published patent application regarding stratification and treatment of the majority of breast cancer patients based on their estrogen receptor alpha status.

Research and Development Findings Mr. Dimmler presented the Company’s findings resulting from its integrative pharmacology capability. Ore Pharmaceuticals uses a multi-pronged approach to discover new therapeutic indications for drugs and drug candidates. The Company has evaluated more than 100 compounds and, for 28 of those compounds, has found a potential new therapeutic use. To date, eight of those compounds have yielded positive results for the potential new therapeutic use in in vivo efficacy tests, and four additional compounds are currently being tested in such models. Ore Pharmaceuticals expects to acquire two to three of these compounds each year for its own clinical development pipeline.

Pipeline Status Ore Pharmaceuticals’ lead drug candidate in its development pipeline is GL1001, a first-in-class, orally administered small molecule. Mr. Dimmler presented preclinical data validating the beneficial effect of GL1001 in a model of ulcerative colitis, and showing the protective effect of GL1001 on gastritis induced by nonsteroidal anti-inflammatory drugs. Ore Pharmaceuticals plans to submit an investigational new drug (IND) application to the FDA in late June and, pending approval, will proceed with a clinical trial of GL1001 in September. The Company plans to acquire and then out-license additional compounds for its development pipeline.

AT1-R Status and Background Mr. Dimmler also discussed the Company’s patent applications related to angiotensin II type I receptor (AT1-R) status as a determinant for stratifying and treating infiltrating ductal carcinoma (IDC) of the breast. Ore Pharmaceuticals has discovered a correlation, in patients with IDC of the breast, between estrogen receptor alpha positive (ER+) status and angiotensin II type I receptor (AT1-R) mRNA expression. The Company’s scientists found that upregulation of AT1-R is present in IDC patients who are ER+ and that ER+ IDC tumor cells responded to pharmacologic intervention with AT1-R antagonists. Ore Pharmaceuticals has supported its findings using in vitro and in vivo models. The findings could help stratify breast cancer patients, thereby facilitating more effective treatment with AT1-R antagonists either alone or in combination with other therapies. The Company’s patent filing claims include: A method of selecting female breast cancer patients for appropriate treatment A method for treating a segment of breast cancer patients A method for determining whether breast cancer tumors are responsive to selective estrogen receptor modulator treatment Mr. Dimmler also presented preclinical data showing that the activity of an AT1-R antagonist (candesartan, a hypertension drug) is similar to that of tamoxifen, a selective estrogen receptor modulator used in treating breast cancer for decades. The Company has additional studies under way in other breast cancer models, and is seeking to out-license the intellectual property to a pharmaceutical company with a currently marketed angiotensin II type I receptor antagonist.

Breast cancer is the leading cause of cancer-related mortality among women worldwide. In 2006, more than 450,000 cases of the disease were diagnosed in the seven major pharmaceutical markets, 75% of which were diagnosed as infiltrating ductal carcinoma, a cancer type with a propensity to metastasize via the lymphatic system to other tissues and organ systems. Despite recent drug approvals in the adjuvant and metastatic setting, high unmet needs still persist for this tumor type as the overall survival rate remains below five years.

Charles L. Dimmler, III, Ore Pharmaceuticals CEO and President, commented, “Ore Pharmaceuticals is advancing drug candidates based on our proprietary integrative pharmacology. Our program identifies new indications for safe, undervalued drug candidates, and, we believe, could extend the value and competitive viability of marketed drugs. We are pleased with the data related to GL1001 and believe it is an excellent candidate for out-licensing or co-development in IBD and related diseases, which are areas of large unmet medical need. Additionally, our AT1-R findings represent an opportunity to extend the use and patent life of existing therapies while offering significant benefit to a large number of breast cancer patients.” Presentation Available Mr. Dimmler’s presentation is archived on the Ore Pharmaceuticals web site at www.orepharma.com.

Ore Pharmaceuticals Overview Ore Pharmaceuticals is a commercial drug development company. We apply our proprietary know how in integrative pharmacology to identify potential new uses for drug candidates. Our goal is to meet the demands of the pharmaceutical industry by supplying development stage drug compounds to enrich drug development pipelines. We do this in two ways: We identify uses for stalled or failed drug compounds provided by our pharmaceutical partners, and, for our own pipeline, we identify new uses for drug compounds available in the public domain. Our own pipeline may also include compounds that our pharmaceutical partners decide not to develop for new uses we identify. We currently have one compound, GL1001, in our own development pipeline for which we have identified potential new therapeutic uses to treat gastrointestinal inflammation, including inflammatory bowel disease (IBD, including ulcerative colitis and Crohn’s disease) and other conditions. GL1001 has shown indications of efficacy at relevant doses in in vivo testing for IBD. We intend to initiate clinical testing of GL1001 in 2008 while actively seeking to out-license or partner the further clinical development and commercialization of the compound. Visit us at orepharma.com or call 1-877-ORE-PHRM.


<< Back

http://ih.advfn.com/p.php?pid=nmona&cb=1211203605&article=26389702&symbol=N%5EORXE

How long do these links last?

[Stock]

61k bid? at .34. That's different.

[keitern]

Sorry for error, should have read:

"As of the end of the first quarter the company had .86/share, in cash. Including the 3 million due about a year from now from Ocimum(13 months) they had .97/share, and market cap is roughly 33% of that."

[keitern]

As of the end of the first quarter the company had .86/share, roughly 62% of market cap in cash. Including the 3 million due about a year from now from Ocimum(13 months) they had .97/share, roughly 66% of market cap in cash.

Something to keep in mind:
"we hold an equity investment in one company (Xceed Molecular, formerly MetriGenix) with a remaining book value of $3.0 million as of December 31, 2007"
Keep in mind that book value is is just that.

I am certainly not saying this is a buy, although I own shares at .45 average, down over 25% now.

I think Miller wanted to liquidate or sell the company but I cannot be certain. His .72 shares look attractive now. The threat with him was that he could have put up a new slate for the BOD with his ownership of 15% and that could have changed the course of the company, something that the BOD was unanimously against.

[Stock]

Ore Pharmaceuticals to Announce First Quarter 2008 Financial Results on April 25, 2008
Friday April 18, 2:48 pm ET


GAITHERSBURG, Md.--(BUSINESS WIRE)--Ore Pharmaceuticals Inc. (NASDAQ:ORXE - News) announced today that it will release first quarter 2008 financial results on Friday, April 25, 2008 at 6:00 a.m. Eastern Time, before the open of the U.S. financial markets.
The Company will hold a related conference call and webcast, scheduled for 10:00 a.m. Eastern Time on the same day, to discuss the financial results. The conference call will be open to investors, analysts, members of the media, and the general public.

Conference Call Details:

Dial-In: 866.770.7051 Domestic
617.213.8064 International
Passcode: 39203680

Replay Dial-In: 888.286.8010 Domestic
617.801.6888 International
Passcode: 93000915
Available through May 9, 2008

Webcast: Please go to http://www.orepharma.com/investors/confcalls.cfm within 15 minutes prior to the call and select the webcast link.


An archived webcast of the conference call will also be available under the Investors section of the Company's website at www.orepharma.com.


Ore Pharmaceuticals Overview

Ore Pharmaceuticals is a leading drug repositioning and development company. We apply our proprietary know how in integrative pharmacology to identify potential new uses for drug candidates. Our goal is to meet the demands of the pharmaceutical industry by supplying development stage drug compounds to enrich drug development pipelines. We do this in two ways: We identify uses for stalled or failed drug compounds provided by our pharmaceutical partners, and, for our own pipeline, we identify new uses for drug compounds available in the public domain. Our own pipeline may also include compounds that our pharmaceutical partners decide not to develop for new uses we identify. We currently have one compound, GL1001, in our own development pipeline for which we have identified potential new therapeutic uses to treat inflammatory bowel disease (IBD, including ulcerative colitis and Crohn’s disease) and other conditions. GL1001 has shown indications of efficacy at relevant doses in in vivo testing for IBD. We intend to initiate clinical testing of GL1001 in 2008 while actively seeking to out-license or partner the further clinical development and commercialization of the compound. Visit us at orepharma.com or call 1-877-ORE-PHRM.





Contact:
Ore Pharmaceuticals Inc.
Philip L. Rohrer, Jr. (investors)
Chief Financial Officer
301-361-4400
[e-mail]
or
Christopher Culotta (investors and media)
Senior Director, Strategic Communications
240-361-4433
[e-mail]

--------------------------------------------------------------------------------
Source: Ore Pharmaceuticals Inc.

[keitern]

News required to move IMO. Hopefuly the GL1001 IND filing. Perhaps a ORXE move to establish a IR front with news to kick it off. They are aware that they need work on the IR front but know also that they need some solid news before putting it in place.
I think they could buy another 4 million shares for a couple million of their cash.
They know that it won't take 2 years for them to find out if the DR thing will work. They will know sooner.

[Stock]

It's a very thinly traded stock. Hard to get in, hard to get out.

People who thought they were buying support, got nervous when some lower level was reached and dumped for losses. In a hurry. Large orders. 10,000 share sell orders can move this stock 10 cents down in a hurry. The AX here loves traders like this.

I like these kind of trades, personally. I just put low bids and wait it out. There are a lot of people that don't have the patience for that.

[surf1944]

Lesson learned here, never follow biotech insiders, "they know not what they want". Should have know, they get too wrapped up in the science and not the product to market to profits "thingy".

[Stock]

Last Trade: 0.560 Change: 0.040 ( +7.692 %)

Previous Close: 0.520 Today's Open: 0.540

# of Trades: 119

Volume: 126,379

Avg. # of Trades: 113

Avg. Daily Volume: 104,587

Bid: 0.560 Bid Size: 100

Ask: 0.570 Ask Size: 13,000

Day High: 0.569 Day Low: 0.500

52 Week High: 0.910 52 Week Low: 0.450

Market Cap: 18.02M

[acgood]

Lloyd Miller resigns from board and company buys back all of his holdings (>4 million shares) at 70 cents...trailing 30 day average price. 8k at link below. cites diagreement about future of company after genomics sale. expensive and painful use of cash but maybe necessary to move forward


http://www.genelogic.com/investors/secfilings.cfm

[keitern]

Nabbed a few K at .45 at open somehow.

[keitern]

Nice to know:

http://investorshub.advfn.com/boards/read_msg.asp?message_id=24839304

[keitern]

I'll buy $1.12 for $0.52.

[keitern]

I agree that the trade is thin, that the prices are irrational, and that it will get better but I doubt there are many out there intentionally trying to short this stock or sell it down because it would be equally hard for them to work their way out of it and the risk is there for them too. I think it is primarily margin call related.
I think we recover before their modest cash burn makes the stock less compelling from a strictly cash in the bank perspective. Good news would be big here.

[Stock]

One other thing -- seems to me that a hadge fund strategy or somebody out there flipped a switch to short every EPS negative biotech stock under a dollar a share last week. From the git-go on Monday, there was a pretty aggressive bid assault this past week all over the place... several stocks I watch were under pressure.... Look for a weak week ahead and recovery after that... if "they" are able to cover... or... even better... with ORXE, the trade is so thin, maybe nobody will panic sell to these bastards and make them cover a lot higher...........

[Stock]

Nice work. I would say that settles it in my mind then. Thanks for clearing it up. So ORXE shares are trading at 50% of cash and near-cash reserves, then?

[keitern]

Spoke with CFO.

[acgood]

Thanks.. I had meant to do that as well. good news clearly. here's hoping for something positive in 08

[Stock]

Thanks. Did you call or email the company to verify it? Or use some other method? I'm sorry I'm such a doubting Thomas.

[keitern]

>>As of December 31, 2007, the Company had $32.8 million in combined cash, cash equivalents and marketable securities available-for-sale<<

Verified that the 3mil additional payment due in about a year is not included in this number. If you include the 3mil the number is 35.8 or about $1.11/share in cash.

GLTY

[Stock]

Here comes some panic selling

[Stock]

ORXE's Position in the Biotechnology & Drugs Industry

[surf1944]

SCHEDULE 13D/A (14.3% owner)

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0000950123%2D08%2D002428%2Etxt&FilePath=%5C2008%5C03%5C03%5C&CoName=GENE+LOGIC+INC&FormType=SC+13D%2FA&RcvdDate=3%2F3%2F2008&pdf=